June 19, 2021 ~ TrialSite News ~
UK-based Meta Analysis Peer Reviewed & Published Suggests Ivermectin A Key Public Health Weapon in the War Against COVID-19
Just published in the peer-reviewed American Journal of Therapeutics, Dr. Tess Lawrie, an expert in medicinal evidence, along with other experts in population health and gastroenterology out of the United Kingdom (UK), conducted a comprehensive meta-analysis involving the certainty of evidence using an approach known as GRADE, which led to the focus on twenty-four ivermectin-centered randomized controlled trials involving 3,406 participants. The authors concluded based on this extensive review that ivermectin actually reduced the risk of death compared with no ivermectin (average risk ratio 0.38, 95% CI 0.19-0.73; n = 2438; I2 = 49%; moderate-certainty evidence). This result, posits Dr. Lawrie and team, confirmed via trial sequential analysis employing what was the same DerSimonian-Laird method behind the unadjusted analysis. The authors also ran their findings against a trial sequential analysis employing the Biggerstaff-Tweedie method. They found low-certainty evidence that ivermectin prophylaxis (as a preventive method) actually lowered infection association with SARS-CoV-2, the virus behind COVID-19, by an average of 86% (95% CI 79-91%). Also, the team’s findings reveal that the evidence for secondary outcomes, such as efficacy associated with “need for mechanical ventilation” is less compelling; however, effective estimates for “improvement” and “deterioration” point to the positive impact of ivermectin use. The authors found little safety risk as reports of severe adverse events were rare among the reviewed studies.